Roche says Ale­cen­sa helps keep ALK-pos­i­tive lung can­cer at bay af­ter surgery as it looks to ex­pand la­bel

Roche’s alec­tinib, mar­ket­ed as Ale­cen­sa, helped cer­tain lung can­cer pa­tients stay dis­ease-free for longer fol­low­ing surgery in a Phase III study, the big phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.